Recent Quotes (30 days)

You have no recent quotes
chg | %

Pacgen Life Science Corp  

(Public, CVE:PBS)   Watch this stock  
Find more results for CVE:PGA
0.0250
0.0000 (0.00%)
Jul 30 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.00 - 0.09
Open     -
Vol. 0.00
Mkt cap 1.18M
P/E     -
Div/yield     -
EPS 0.00
Shares 47.22M
Beta 0.49
Inst. own     -

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - 228.54%
Operating margin - 237.47%
EBITD margin - 242.79%
Return on average assets -58.07% 63.28%
Return on average equity - -
Employees 10 -
CDP Score - -

Address

Suite 1500, 701 West Georgia St.
VANCOUVER, BC V7Y 1C6
Canada
+1-604-4364388 (Phone)
+1-604-4364380 (Fax)

Website links

Description

Pacgen Life Science Corporation is Life Science Company. The Company is focused on the commercialization of biomedical product and services. The Company´┐Żs product includes Fit X1 Series, Electronic Pipettes, A+Pipette Controller. The Company reported positive results from its Phase IIb dose-ranging clinical trial for its lead product candidate, PAC-113, a anti-fungal drug. PAC-113 is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. This peptide alters the permeability of fungal cell membranes causing cell death. PAC-113 is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. This peptide alters the permeability of fungal cell membranes causing cell death.

Officers and directors

Chung-Yu Yu Wang Chairman of the Board, Interim President and Chief Executive Officer
Christina Yip Chief Financial Officer, Corporate Secretary
Ming Sun Liu Ph.D. Director
Jeng-Horng Her Independent Director
Min-Chih Hsuan Independent Director
Age: 60
Frederick Huang Independent Director
Telvin Ju Ph.D. Independent Director